医学
内科学
置信区间
达沙替尼
淋巴细胞白血病
伊马替尼
胃肠病学
临床试验
统计显著性
前瞻性队列研究
肿瘤科
白血病
髓系白血病
作者
Yoshikiyo Ito,Hidetoshi Ozawa,Tetsuya Eto,Toshihiro Miyamoto,Tomohiko Kamimura,Ryo Ogawa,Naoyuki Uchida,Atsusi Wake,Tomoaki Fujisaki,Yuju Ohno,Ken Takase,Hirokazu Okumura,Yasushi Takamatsu,Noriaki Kawano,Koichi Akashi,Koji Nagafuji
摘要
The prognostic significance of IKZF1plus in adult Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) patients had remained to be clarified.We conducted a prospective, multicenter study, the ALL/MRD2008 trial, and investigated the clinical significance of IKZF1plus .From December 2008 to November 2013, 38 untreated Ph+ ALL patients were enrolled. At the end of the induction, 97.4% of patients (37/38) achieved complete hematological remission, with MRD-negativity of 48.6% (18/37). There were 19 patients with IKZF1plus , 13 with IKZF1 deletion alone (ΔIKZF1) and 4 with no IKZF1 deletions (no ΔIKZF1). The probability of 3-year DFS and OS in these Ph+ ALL patients were 50% (95% confidence interval [CI], 33-65) and 55% (95% CI, 38-69), respectively. There was no significant difference between IKZF1plus , ΔIKZF1, and no ΔIKZF1 in DFS (47%, 54%, 75% [p = .63]) or OS (47%, 62%, NA [p = .39]).We revealed no relationship between IKZF1plus status and survival outcomes in Ph+ ALL patients treated with imatinib/dasatinib combination chemotherapy. Further investigations are warranted to clarify the prognostic significance of IKZF1plus in adult Ph+ ALL patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI